vidence from multiple paradigms indicates that estrogen has potent impact on endothelial cell function. The hormone activates signaling by endothelium, and it modifies endothelial cell growth, migration, and apoptosis. These actions are primarily mediated by estrogen receptor (ER) subtypes ␣ and ␤, which classically function as transcription factors. [1] [2] [3] We have demonstrated that ER␣ and ER␤ are expressed in endothelium, and that subpopulations of ER␣ and ER␤ reside in endothelial caveolae/lipid rafts. 4, 5 One of the most thoroughly delineated targets of endothelial ER action is endothelial nitric oxide synthase (eNOS). eNOS transcription is upregulated by the activation of classical ER and estrogen-related receptor ␣ 1 in processes that involve diverse regulatory elements within the 5Ј flanking region of the eNOS gene. 6, 7 In addition, eNOS activity is rapidly stimulated by ER␣ or ER␤ ligand activation in endothelial caveolae. 4, 5 Through these multiple mechanisms estrogen enhances the production of the important atheroprotective molecule NO. 8 In contrast to the detailed understanding of the basis of estrogen action on endothelial NO production, considerably less is known about the equally potent ability of the hormone to stimulate endothelial prostacyclin synthesis. This process is critical to the overall impact of estrogen on vascular health. 9 We have previously demonstrated that estrogen acutely activates endothelial prostacyclin synthesis through an ER␤-dependent, calcium-dependent process. 10 We have also shown that estrogen upregulates the expression of the rate-limiting enzyme in prostacyclin synthesis, cyclooxygenase type 1 (COX-1) in endothelial cells, resulting in enhanced basal and agonist-stimulated prostacyclin synthesis. We have further demonstrated that this is mediated by increases in steady-state COX-1 mRNA levels, which are not related to changes in mRNA degradation, thus implicating transcriptional processes. 11 However, the molecular mechanisms by which COX-1 is upregulated by estrogen are unknown.
The purpose of the present study was to determine the processes by which COX-1 expression is upregulated in endothelium by estrogen. The 5Ј flanking sequence of the COX-1 gene lacks estrogen response elements (EREs) or ERE half-palindrome motifs. 12 The hypothesis was therefore raised that estrogen activates COX-1 gene transcription via the involvement of putative Sp1 elements, which are prevalent in the COX-1 promoter and which mediate the estrogen responsiveness of certain genes. 13 In addition to testing this hypothesis, experiments were performed to determine the role of ER␣ and ER␤ in this process. The specific cis DNA sequences involved in the estrogen response were also identified, along with nuclear proteins that are involved. Furthermore, studies were done to begin to determine the features of ER␣ that play a role in mediating COX-1 expression.
Materials and Methods

Cell Culture
Experiments were performed in primary ovine endothelial cells obtained as previously described and studied at passage 4 to 6. 14 These cells have been used previously in studies of COX-1 regulation. 11, 15 In experiments evaluating the actions of estrogen receptor mutants, primary endothelial cell cultures were specifically selected that had negligible expression of endogenous ER␣ or ER␤ by immunoblot analysis.
Construction of Reporter and Receptor Plasmids and Mutagenesis
The basis of estrogen-induced activation of COX-1 transcription was investigated using a 2075-base pair fragment (Ϫ2095 to Ϫ21 relative to the ATG codon, A as ϩ1) of the human COX-1 5Ј flanking region inserted into KpnI/HindIII sites of the luciferase reporter gene plasmid, pGL2 (Promega Corp) to yield the full-length promoter-reporter plasmid denoted as Ϫ2095COX-1-Luc. Two 5Ј deletion mutants were also studied including 1241 (Ϫ1261 to Ϫ21) or 117 (Ϫ137 to Ϫ21) base pairs of 5Ј flanking sequence of COX-1, designated Ϫ1261COX-1-Luc and Ϫ137COX-1-Luc, respectively. The COX-1 genomic sequences for these plasmids were obtained from COX-1 promoter reporter constructs originally made using pXP1. 12 Site-directed mutants were also generated of the putative Sp1 element at Ϫ111, the putative Sp1 element at Ϫ89, or of both elements (see online data supplement available at http://circres.ahajournals.org). 12 In studies of the role of estrogen receptors in COX-1 gene transcription, cells were cotransfected with cDNAs for wild-type human ER␣ inserted into pCDNA3.1 4 or deletion mutants of ER␣. These included a mutant lacking the two primary NLS, NLS 2 and 3 (ER␣⌬250 -274), a mutant lacking the DNA binding domain (ER␤⌬ 185-251), and an N-terminal deletion mutant lacking residues 1 to 175 (ER␤⌬1-175) (see online data supplement and online Figure I ). In selected experiments, cells were transfected with mouse ER␤ cDNA cloned into pCDNA3.1. 5
Cell Transfection and Reporter Activity
Cell transfection was performed using methods that have been previously reported. 16 Twenty four hours later, the cells were placed in media containing charcoal-stripped serum and were treated with either vehicle, 17␤-estradiol (E 2 , 10 Ϫ12 to 10 Ϫ6 mol/L), or E 2 plus ICI 182,780 (10 Ϫ5 mol/L) for 48 hour. The cells were lysed, extracts were centrifuged at 10 000g, and luciferase and ␤-galactosidase activity were measured. 17, 18 The results are normalized as relative luciferase light units/␤-galactosidase activity. In selected wells, the cells were transfected with pGL2-Control Vector (Promega Corp) to serve as a positive control for luciferase expression. In preliminary studies, 17␣-estradiol had no effect on promoter activity. In experiments focused on the role of ER, sham plasmid or cDNAs for wild-type or mutant ER were cotransfected with the promoterreporter constructs and pSV-␤-Gal, and equal expression of ER forms was confirmed by immunoblot analysis. 4 
Electrophoretic Mobility Shift Assays
After 0 to 48 hours treatment of endothelial cells with vehicle or 10 Ϫ8 mol/L E 2 , nuclear extracts were prepared. 16 Oligonucleotide probes were generated and added to incubations of nuclear extracts using methods that have been previously reported. 16 In competition studies, excess wild-type, mutant, or unrelated oligonucleotides were added in 2-to 200-fold molar excess before the addition of the 32 P-labeled probe. The wild-type Ϫ111 Sp1 probe was 5Ј-GAGGGAGGAGCGGGGGTGGAGCCGGGGGAA-3Ј (upper strand) and the mutant probe was 5Ј-GAGGGAGGAGCG-GTTTTAGAGCCGGGGGAA-3Ј. The wild-type Ϫ89 Sp1 probe was 5Ј-GGGGGAAGGGTGGGGAGGGGATGGGCTGGA-3Ј (upper strand), and the mutant probe was 5Ј-GGGGGAAGGGT-GTTTAAGGGATGGGCTGGA-3Ј.
To identify the nuclear proteins that bound to the putative Sp1 domains, supershifting of the DNA-protein complex was performed. For ER␣, 2 L of MAB461 (Chemicon International Inc) or unrelated IgG was added. For Sp1, Sp3, AP-2␣, and AP-2␥, 2 L of antiserum to the respective transcription factors was added. The antibodies were 2 g/L from Santa Cruz Biotechnology, Inc, and with the exception of Sp3, all were monoclonal. To confirm effective supershifting with antibody to Sp1, additional experiments were performed with an Sp1 probe from the eNOS promoter (5Ј-GGATAGGGGCGGGGCGAGG-3Ј, upper strand). 16 All nuclear protein-DNA complexes were resolved on 5% nondenaturing polyacrylamide gels containing 1ϫ Tris borate/EDTA buffer. Dried gels were exposed to Kodak XAR film for autoradiograpy.
Statistical Analysis
Data for promoter activity were analyzed by ANOVA and NeumanKeuls post hoc testing. 19 Results are expressed as meanϮSEM. All stated differences achieved statistical significance at the 0.05 level of probability or less.
Results
COX-1 Promoter Activation by Estrogen
To determine whether estrogen activates COX-1 transcription, the effects of the hormone on the activation of the full-length promoter (Ϫ2095COX-1-Luc) were determined. The levels of basal promoter activity obtained with Ϫ2095COX-1-Luc was at least 3-fold greater than with vector alone, and activity with vector alone was not altered by hormone treatment (data not shown). In cells transfected with Ϫ2095COX-1-Luc, treatment with 10 Ϫ8 mol/L E 2 for 48 hours caused a 2.6-fold increase in promoter activity that was fully reversed by concomitant treatment with ICI 182,780 ( Figure 1A) . In additional studies, the dose-response to E 2 was evaluated ( Figure 1B) . Activation was observed at 10 Ϫ10 mol/L E 2 , and maximal response occurred with 10 Ϫ8 mol/L E 2 . Minimal stimulation of promoter activity was seen with 10 Ϫ6 mol/L E 2 , indicating a biphasic dose-response.
To further determine the role of ER in COX-1 gene modulation, experiments were done in endothelial cells overexpressing either ER␣ or ER␤ ( Figure 1C ). Relative to the responses seen with endogenous ER action in shamtransfected cells, there was a 2.3-fold greater E 2 -mediated promoter activity after ER␣ overexpression. Similarly, there was a 2.2-fold enhancement of the E 2 response with overexpression of ER␤. As such, both ER subtypes are capable of activating COX-1 transcriptional transactivation.
Promoter Elements Required for Regulation by Estrogen
To determine the elements in the COX-1 promoter required for estrogen responsiveness, the activities of 5Ј deletion mutants were evaluated in endothelial cells. Basal promoter activity fell by 63% with deletion from Ϫ2095 to Ϫ1261, and it fell a comparable 70% with deletion from Ϫ2095 to Ϫ137 (Figure 2A ). However, the relative capacity for E 2 -stimulated promoter activity was conserved with deletion from Ϫ2095 to Ϫ1261, with the hormone causing similar 2.4-fold and 2.6-fold increases in activity over basal, respectively. In addition, there was continued conservation of E 2 activation of the promoter with deletion to Ϫ137, with Ϫ137COX-1-Luc displaying a 2.8-fold response to hormone. Importantly, ER antagonism with ICI 182,780 reversed estrogen responses in all cases. To further implicate the proximal promoter in hormone action, additional experiments were done using Ϫ2095COX-1-Luc and Ϫ137COX-1-Luc in cells cotransfected with ER␣ cDNA (Figure 2B ). With ER␣ overexpression, E 2 -stimulated activity of Ϫ2095COX-1-Luc was raised by 2.4-fold. Similarly, with overexpression of the receptor the E 2 -induced activity of Ϫ137COX-1-Luc increased by 2.2-fold.
Inspection of the proximal COX-1 promoter reveals a lack of estrogen response elements (ERE) or ERE half-palindrome motifs known to mediate the estrogen responsiveness of certain genes. 20 However, there is a potential Sp1 binding site at Ϫ111 and another at Ϫ89, 12 and Sp1 is known to mediate estrogen responsiveness in the absence of ERE-like motifs in certain paradigms. 13 Because E 2 -induced activation of the promoter in endothelial cells was conserved with 5Ј deletions, which retained these domains, site-directed mutants of either or both of these putative Sp1 elements within Ϫ2095COX-1-Luc were tested. First, the basal activity of mutated promoter sequences was evaluated ( Figure 2C ). Compared with full-length wild-type promoter (Ϫ2095COX-1-Luc), mutation of the Ϫ111 Sp1 caused a 58% decline in activity, mutation of the Ϫ89 Sp1 yielded a 72% fall, and mutation of both elements caused a 53% decrease. Estrogen-stimulated promoter activity expressed relative to the level of basal activity for the same construct is shown in Figure 2D . Mutation of the Sp1 element at Ϫ111 caused a decline in E 2 -induced activity of 43%, and mutation of Ϫ89 Sp1 resulted in a 73% decline in the E 2 response. Mutation of both domains yielded an 88% fall in E 2 -induced promoter activity.
Evaluation of Relevant Nuclear Proteins
To evaluate the nuclear proteins in endothelial cells involved in estrogen actions mediated by the consensus Sp1 elements of the COX-1 promoter at Ϫ111 and at Ϫ89, electrophoretic mobility shift assays were performed. Incubation of nuclear extracts from E 2 -treated endothelial cells (48 hours) with a double-stranded oligonucleotide probe encompassing the putative Sp1 site at Ϫ111 resulted in the appearance of one major DNA-protein complex that was diminished by 200-fold molar excess of unlabeled probe ( Figure 3A, left) . In contrast, three minor complexes were formed with mutated Ϫ111 Sp1 site probe. The use of mutated oligonucleotide as a competitor did not prevent the formation of the major complex by the wild-type probe ( Figure 3A , right). Incubation of nuclear extracts with a probe containing the putative Sp1 site at Ϫ89 resulted in the appearance of one major DNA-protein complex that were prevented by 200-fold molar excess of unlabeled probe ( Figure 3B , left). The complex was minimally formed with mutated Ϫ89 Sp1 DNA probe, and the mutated oligonucleotide only partially prevented the formation of the complex by the wild-type probe ( Figure 3B, right) .
To identify the endothelial nuclear proteins involved in complex formation with the presumptive Ϫ111 Sp1 and the Ϫ89 Sp1COX-1 promoter elements, supershift analyses were done. Two different antisera to Sp1 did not cause supershifting of either the Ϫ111 Sp1 protein-DNA complex or the Ϫ89 Sp1 protein-DNA complex ( Figure 4A and 4B, left). To provide a control for supershifting of Sp1, a study was performed using the same endothelial nuclear proteins and the Sp1 element from the proximal eNOS promoter. With the Sp1 domain from eNOS, supershifting was observed as previously described (data not shown). 16 In an effort to identify other potential nuclear proteins relevant to gene regulation by Sp1 elements, the effects of antisera to Sp3 were also assessed, and supershifting was not evident for either the Ϫ111 Sp1 protein-DNA complex or the Ϫ89 Sp1 protein-DNA complex ( Figure 4A and 4B, middle) . In studies of potential involvement of AP-2␣ or AP-2␥, which have consensus binding sequences similar to Sp1, [21] [22] [23] [24] antisera to either protein did not cause supershifting of the Ϫ111 Sp1 protein-DNA complex ( Figure 4A, right) . However, antisera to AP-2␣ caused supershifting of the Ϫ89 Sp1 protein-DNA complex ( Figure 4B, right) . In experiments comparing nuclear proteins from endothelial cells treated with vehicle vs 10 Ϫ8 mol/L E 2 for 48 hours, there was no difference in the overall formation of the Ϫ111 Sp1 protein-DNA complex or the Ϫ89 Sp1-protein DNA complex, and the supershifting of AP-2␣ in the Ϫ89 Sp1 protein-DNA complex was also similar (data not shown).
The contribution of ER␣ to complex formation was also assessed by supershift analyses. Using nuclear proteins from cells treated with E 2 for 48 hours, antiserum to ER␣ shifted both the Ϫ111 Sp1 protein-DNA complex and the Ϫ89 Sp1 protein-DNA complex, whereas an unrelated IgG did not ( Figure 5A and 5B, left). In evaluations of the temporal features of ER␣ involvement in complex formation, studies of nuclear proteins from cells treated with E 2 for 0 versus 6 hours yielded comparable supershifting of ER␣ from the Ϫ111 Sp1 complex ( Figure 5A, right) . In contrast, the supershifted bands for ER␣ in the Ϫ89 Sp1 complex differed at 0 and 6 hours of E 2 exposure; there was less prevalence of a rapidly migrating supershifted complex and greater abundance of a slowly-migrating supershifted complex after 6 hours of E 2 treatment versus control ( Figure 5B, right) .
Features of ER␣ Required for Modulation of COX-1 Transcription
There are multiple mechanisms by which ER␣ regulates gene transcription. 13, 20 To begin to elucidate the features of the receptor necessary for modulation of COX-1, experiments were performed in a primary endothelial cell culture selected to have negligible endogenous ER␣ or ER␤ into which ER␣ mutant constructs were cotransfected along with Ϫ2095COX-1-Luc. In cells transfected with sham plasmid for wild-type ER␣, E 2 caused no change in the activity of Ϫ2095COX-1-Luc ( Figure 6A ). In contrast, cells transfected with wild-type ER␣ displayed a 2.5-fold increase in promoter activity with E 2 . In simultaneous comparisons of wild-type ER␣ and ER␣⌬185-251, E 2 caused a 1.8-fold increase in promoter activity in cells expressing wild-type receptor and there was a 7-fold increase in activity with E 2 in cells expressing ER␣⌬185-251 ( Figure 6B ). Additional independent studies revealed a 2.3-fold stimulation of promoter activity with E 2 via wild-type ER␣ and a markedly greater 9.2-fold stimulation in cells expressing ER␣⌬250 -274 ( Figure 6C ). In contrast, the N-terminal truncation mutant of ER␣, ER␣⌬1-175, was incapable of E 2 -induced activation of the COX-1 promoter ( Figure 6D ).
Discussion
Estrogen causes upregulation of COX-1 expression in endothelial cells that is instrumental to the impact of the hormone on vascular function. 9 We have previously demonstrated that this is mediated by an increase in steady-state levels of COX-1 mRNA, and that the degradation of the mRNA is unaltered. 11 In the present study, we show that E 2 activates COX-1 gene transcription in an ER-dependent manner. We further demonstrate that the process entails unique EREindependent mechanisms, providing new insights into the complex nature of E 2 actions in endothelium.
Role of ER␣ and Regulatory Elements on COX-1 Gene
In transient transfection experiments in endothelial cells with a construct containing the human COX-1 promoter fused to luciferase, we have observed E 2 -induced promoter activation of sequence residing between Ϫ2095 and Ϫ21 of the 5Ј flanking sequence relative to the ATG codon. Experiments with ICI 182,780 indicated that the process is ER-dependent, and the dose-response was biphasic with a threshold concentration of 10 Ϫ10 mol/L and maximal activation at 10 Ϫ8 mol/L E 2 . The biphasic dose-response mimics that found previously for changes in COX-1 mRNA abundance with E 2 . 11 Interestingly, the nongenomic activation of prostacyclin synthesis by E 2 does not display a biphasic dose response, 10 suggesting quite different kinetics for genomic versus nongenomic E 2 modulation of prostacyclin synthesis in endothelial cells. Cotransfection studies further indicated that the COX-1 promoter response can be Ϫ8 mol/L for 48 hours) endothelial cells. Two different antisera to Sp1, an antiserum to Sp3, an antiserum to AP-2␣, or an antiserum to AP-2␥ was added to the DNA-nuclear protein complexes formed using oligonucleotide probes containing the consensus Sp1 binding motif at Ϫ111 (A) or the putative Sp1 binding motif at Ϫ89 (B) before electrophoresis. Supershifted complex for AP-2␣ is identified with an arrowhead. Observations were confirmed in three independent experiments. mediated by either ER␣ or ER␤. Thus, COX-1 regulation by E 2 occurs at a physiological concentration of the hormone 8 and via either of the ER subtypes.
To determine the regulatory elements within the COX-1 promoter required for estrogen responsiveness, the activities of progressive 5Ј deletion mutants were evaluated. The capacity for E 2 -stimulated promoter activity was fully conserved with 5Ј deletion from Ϫ2095 to Ϫ1261 and also to Ϫ137. In addition, the enhancement in E 2 response with ER␣ overexpression was similar for Ϫ2095COX-1-Luc and Ϫ137COX-1-Luc. These findings indicate that the estrogen responsiveness of the COX-1 gene resides within the proximal promoter.
Because the 5Ј flanking sequence of the COX-1 gene lacks EREs or ERE half-palindrome motifs, alternative modes of estrogen regulation were contemplated. Within the proximal COX-1 promoter, there are potential Sp1 binding sites at Ϫ111 and at Ϫ89, 12 and Sp1 mediates estrogen responsiveness in the absence of ERE-like motifs in certain paradigms. Sp1 physically associates with ER␣, resulting in increased binding of Sp1 to its DNA site. 13 With mutation of Ϫ111Sp1, E 2 -induced promoter activity was attenuated by 43%, and it was decreased by over 70% with mutation of Ϫ89Sp1 alone and by almost 90% with mutation of both Ϫ111Sp1 and Ϫ89Sp1. These findings indicate that putative Sp elements within the core COX-1 promoter are critical to E 2 -induced upregulation.
Identification of Nuclear Proteins Mediating COX-1 Response
To evaluate the nuclear proteins involved in binding to the proximal consensus Sp1 domains of the COX-1 promoter, electrophoretic mobility shift assays were performed with nuclei from E 2 -treated endothelial cells and oligonucleotide probes encompassing either Ϫ111Sp1 or Ϫ89Sp1. With Ϫ111Sp1, one major DNA-protein complex was formed with wild-type probe that was less apparent with mutant probe. Because the identical mutation of Ϫ2095COX-Luc yielded a modest decrease in E 2 responsiveness, it suggests that the complex with Ϫ111Sp1 plays a minor role in hormonal regulation of COX-1 expression. With Ϫ89Sp1, a single major DNA-protein complex was formed with wild-type but not mutant probe, and the same mutation in Ϫ2095COX-Luc prevented the majority of E 2 responsiveness either alone or in combination with mutation of Ϫ111Sp1. As such, the complex with Ϫ89Sp1 most likely depicts the principal protein-DNA interaction mediating E 2 induction of the COX-1 gene in endothelium.
To identify the nuclear proteins involved, supershift analyses were done. Antiserum to Sp1did not shift either the Ϫ111Sp1 or the Ϫ89Sp1 probe-nuclear protein complexes. Because Sp3 can interact with ER␣ to mediate Sp1 responses, 13 supershifts for Sp3 were also done that were negative. AP-2 was then considered because Sp1 and AP-2 have similar consensus binding sequences consisting of short GC-rich elements, and Sp1 and AP-2 bind to the same or overlapping regions within a variety of promoters. [21] [22] [23] [24] Furthermore, AP-2␣ and AP-2␥ are both known to be involved in E 2 modulation of gene expression. 25 Antisera to AP-2␣ or AP-2␥ did not shift the Ϫ111Sp1 probe-nuclear protein complex. However, antiserum to AP-2␣ uniquely caused supershifting of the Ϫ89Sp1 probe-nuclear protein complex. Thus, AP-2␣ is likely to play an important role in the modulation of COX-1 gene expression by E 2 .
The participation of ER␣ was also investigated. Antibody to ER␣ supershifted the Ϫ111Sp1 and the Ϫ89Sp1 probenuclear protein complexes, indicating that ER␣ is a component of both complexes. However, differences in overall complex formation were not observed in the absence versus presence of E 2 treatment for 6 or 48 hours, there were only modest changes in the relative quantities of supershifted bands for the Ϫ89Sp1 complex with ER␣ antibody at 0 versus 6 hours of E 2 , and no changes in AP-2␣ recruitment were apparent. Thus, although the current approaches revealed important roles for the proximal Sp1-like elements and for ER␣ and AP-2␣, the exact events activated by ER ligand binding are yet to be elucidated. Recent work using chromatin immunoprecipitation (ChIP) suggests that ER and coregulator association in gene promoters is temporally regulated. ChIP and cell imaging studies further show that members of the steroid receptor coactivator (SRC)-1 family and other coac- tivators may cycle on and off promoters with rapid kinetics. 20, 26 Further experiments are now indicated using strategies including ChIP to interrogate this unique promodulatory role of AP-2␣, which is collaborating with ER and other yet-to-be identified coactivators to target proximal regulatory elements on an important endothelial cell gene.
Features of ER␣-Mediating COX-1 Response
The features of ER␣ required for COX-1 upregulation were also investigated. In studies of primary endothelial cells specifically selected to have minimal endogenous ER, the transient transfection of wild-type receptor caused COX-1 promoter responsiveness to E 2 comparable to that observed at endogenous levels of ER expression. In contrast, a mutant form of ER␣ lacking the DNA binding domain (ER␣⌬185-251) yielded a 4-fold greater E 2 response than wild-type receptor. This finding indicates that E 2 upregulation of COX-1 is independent of direct ER␣-DNA interaction, which is consistent with the involvement of Sp1-like elements and AP-2␣. In addition, a mutant form of ER␣ lacking the two primary nuclear localization signals (ER␣⌬250 -274) displayed 5-fold greater E 2 responsiveness than wild-type receptor. Because ER␣⌬250 -274 (HE257G) has attenuated nuclear localization in the absence or presence of E 2 , 27 this finding suggests that the process may be initiated primarily by cytoplasmic ER␣, and that other mechanisms besides NLS must be responsible for nuclear import of the ER␣-related transcriptional machinery in this paradigm. Furthermore, we found that mutant ER␣ lacking the A-B domains (ER␣ ) was incapable of inducing COX-1 promoter activity. This observation parallels the findings in prior work indicating that the AF-1 region within the A-B domains of ER␣ is important for Sp1 activation. 13, 28 Similar domains within AF-1 may bind Sp1 and AP-2␣, and further detailed mutagenesis will be required to delineate these domains.
The ability of estrogen to upregulate COX-1 expression in endothelium through transcriptional transactivation represents a novel mode of regulation of a gene for which there are few means of dynamic regulation. 29, 30 Our collective observations indicate that this process is independent of direct ER␣-DNA binding, and that it instead entails protein-DNA interaction involving AP-2␣ and ER␣ at proximal regulatory elements within the COX-1 promoter. In addition, cytoplasmic ER␣ may play a key role in this process, and critical receptor elements reside within the amino terminus. As such, ER␣ modulation of COX-1 entails mechanisms that are both shared and unique to the known processes whereby estrogen regulates a variety of gene targets. 20, 26 Further studies in this realm will increase our understanding of both COX-1 regulation and the potent, diverse capacities of estrogen to alter endothelial cell function. 
Additional Figures and Supporting Information
Before testing the ability of ER∀ mutants to modulate COX-1 promoter activity, the classical actions of the mutants were tested in endothelial cells using the estrogen-responsive reporter plasmid ERE-Luc 3 . Whereas reporter activity was increased by 9-fold with E 2 in cells transfected with wild-type ER∀ and the response was prevented by ER antagonism, reporter activity was not stimulated by the hormone in cells expressing the DNA binding domaindeficient mutant, ER∀)185-251 (Supplemental Fig. 1A ). In addition, reporter activity was not stimulated by E 2 in cells expressing ER∀)250-274, which lacks the two primary NLS, NLS2 and
